利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.027 秒)

    HUMANEERED ANTI-FACTOR B ANTIBODY
    1.
    发明申请
    HUMANEERED ANTI-FACTOR B ANTIBODY 有权
    人类抗原B抗体

    公开(公告)号：US20080299114A1

    公开(公告)日：2008-12-04

    申请号：US12049233

    申请日：2008-03-14

    申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

    发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

    IPC分类号： A61K39/395 ,  C07K16/00 ,  A61P11/00 ,  A61P33/00 ,  A61P31/12

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

    摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

    摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

    Humaneered anti-factor B antibody
    2.
    发明授权
    Humaneered anti-factor B antibody 有权
    抗衰老抗B抗体

    公开(公告)号：US07964705B2

    公开(公告)日：2011-06-21

    申请号：US12049233

    申请日：2008-03-14

    申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

    发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

    IPC分类号： C12P21/08

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

    摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

    摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

    HUMANEERED ANTI-FACTOR B ANTIBODY
    3.
    发明申请
    HUMANEERED ANTI-FACTOR B ANTIBODY 审中-公开
    人类抗原B抗体

    公开(公告)号：US20110318337A1

    公开(公告)日：2011-12-29

    申请号：US13115810

    申请日：2011-05-25

    申请人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

    发明人： Woodruff Emlen ,  V. Michael Holers ,  Peter Flynn

    IPC分类号： A61K39/395 ,  A61P11/00 ,  A61P29/00

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/461 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/92

    摘要： This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.

    摘要翻译： 本发明涉及具有降低的免疫原性的受人尊敬的抗因子B抗体及其抗原结合片段。 人类的抗因子B抗体及其抗原结合片段衍生自鼠单克隆抗体1379，其在第三短共有重复（“SCR”）结构域中结合因子B，并通过预防形成的方法选择性地抑制替代补体途径的活化 C3bBb复合物。 本发明还涉及治疗其中补体途径的活化发挥作用的疾病或病症的方法，以及在有需要的个体中选择性抑制替代补体途径活化的方法。

    Systems and methods for collaboratively creating applications using a multiple source file project that can be accessed and edited like a single file
    4.
    发明授权
    Systems and methods for collaboratively creating applications using a multiple source file project that can be accessed and edited like a single file 有权
    使用可以像单个文件进行访问和编辑的多个源文件项目协同创建应用程序的系统和方法

    公开(公告)号：US08453112B1

    公开(公告)日：2013-05-28

    申请号：US12270341

    申请日：2008-11-13

    申请人： Robert Brambley ,  Narciso B. Jaramillo ,  Peter Flynn ,  Rebecca Hauck ,  Rob Adams

    发明人： Robert Brambley ,  Narciso B. Jaramillo ,  Peter Flynn ,  Rebecca Hauck ,  Rob Adams

    IPC分类号： G06F9/44

    CPC分类号： G06F17/24 ,  G06F8/71 ,  G06F17/2288

    摘要： Certain embodiments facilitate collaboration between designers and developers in the creation of software applications. Designers and developers can work on the same multi-file-based software development project, without the designer having to address or even be aware of the multi-file structure of the project or the management of different versions of the project. Instead the designer can receive and send the project as a single file and work with it as if it were a single document. A developer or another user can address conflicts and other versioning issues that may result from collaborators making changes concurrently.

    摘要翻译： 某些实施例便于设计人员和开发人员之间在创建软件应用程序时的协作。 设计人员和开发人员可以在同一个基于多文件的软件开发项目上工作，而设计人员不必处理或甚至意识到项目的多文件结构或项目的不同版本的管理。 相反，设计人员可以接收并发送项目作为单个文件，并将其作为单个文档进行处理。 开发人员或其他用户可以解决协作者同时进行更改可能导致的冲突和其他版本控制问题。

    Electrostatically Controlled Hydrogels
    5.
    发明申请
    Electrostatically Controlled Hydrogels 有权
    静电控制水凝胶

    公开(公告)号：US20090169625A1

    公开(公告)日：2009-07-02

    申请号：US12085049

    申请日：2006-11-14

    申请人： Yihua Bruce Yu ,  Sivakumar Ramachandran ,  Peter Flynn ,  Yiider Tseng

    发明人： Yihua Bruce Yu ,  Sivakumar Ramachandran ,  Peter Flynn ,  Yiider Tseng

    IPC分类号： A61K9/10 ,  A61K38/00 ,  A61K31/7088 ,  A61K31/56

    CPC分类号： A61K8/64 ,  A61K8/042 ,  A61K9/0009

    摘要： The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and while doing so, may entrap a variety of bioactive agents in their native form, such as proteins, DNA, RNA and the like. The hydrogels of the present invention also demonstrate rapid sheer-responsiveness. The hydrogels of the present invention are biodegradable, biocompatible and useful as a biomaterial or drug-delivery device.

    摘要翻译： 本文公开的组合物和方法涉及水凝胶的制造和使用。 所公开的组合物和方法涉及能够通过各种方法进行诱导的水凝胶，例如通过pH，盐和/或混合。 这样的水凝胶能够自组装或共同组装，并且在这样做的时候，可能会捕获各种其天然形式的生物活性剂，例如蛋白质，DNA，RNA等。 本发明的水凝胶也显示出快速的反应性。 本发明的水凝胶是可生物降解的，生物相容的并且可用作生物材料或药物递送装置。